This document has not been cited yet.

1. Atella, V., Belotti, F., & Depalo, D. (2017). Drug therapy adherence and health outcomes in the presence of physician and patient unobserved heterogeneity. Health Economics, 26, 106–126.

2. Barigozzi, F., & Jelovac, I. (2020). Research funding and price negotiation for new drugs. Health Economics. https://doi.org/10.1002/hec.4113.

3. Berta, P., Martini, G., Piacenza, M., & Turati, G. (2020). The strange case of less C‐sections: Hospital ownership, market concentration, and DRG‐tariff regulation. Health Economics. https://doi.org/10.1002/hec.4110.
   Paper not yet in RePEc: Add citation now
   

4. Billette de Villemeur, E., & Versaevel, B. (2019). One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry. Journal of Health Economics, 65, 260–283.

5. Blankart, K. E., & Stargardt, T. (2020). The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. Health Economics. https://doi.org/10.1002/hec.4108.

6. Breyer, F., Costa‐Font, J., & Felder, S. (2010). Aging, health, and health care. Oxford Review of Economic Policy, 26(4), 674–690. https://doi.org/10.1093/oxrep/grq032.

7. Carone, G., Schwierz, C., & Xavier, A. (2012). Cost‐containment policies in public pharmaceutical spending in the EU (European Economy ‐ Economic Papers 2008 ‐ 2015 461). Directorate General Economic and Financial Affairs (DG ECFIN), European Commission, Bruxelles, Europe.

8. Costa‐Font, J., & Vilaplana‐Prieto, C. (2020). ‘More than one red herring’? Heterogeneous effects of ageing on health care utilisation. Health Economics. https://doi.org/10.1002/hec.4035.
   Paper not yet in RePEc: Add citation now
   

9. Costa‐Font, J., Mossialos, E., & Rudisill, C. (2009). When is the internet a valued communication device for health information in Europe? Economics of Innovation and New Technology, 18(5), 429–445.

10. Depalo, D. (2020). Explaining the causal effect of adherence to medication on cholesterol through the marginal patient. Health Economics. https://doi.org/10.1002/hec.4030.

11. Di Novi, C., Leporatti, L., & Montefiori, M. (2020). Older patients and geographic barriers to pharmacy access: When nonadherence translates to an increased use of other components of health care. Health Economics. https://doi.org/10.1002/hec.4031.

12. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33.

13. Gamba, S., Pertile, P., & Vogler, S. (2020). The impact of managed entry agreements on pharmaceutical prices. Health Economics. https://doi.org/10.1002/hec.4112.

14. Hughes, D. A., Bagust, A., Haycox, A., & Walley, T. (2001). The impact of non‐compliance on the cost‐effectiveness of pharmaceuticals: A review of the literature. Health Economics, 10(7), 601–615. https://doi.org/10.1002/hec.609.

15. Hugonnier, J., Pelgrin, F., & St‐Amour, P. (2020). Closing down the shop: Optimal health and wealth dynamics near the end of life. Health Economics, 29(2), 138–153.

16. Jobjörnsson, S., Forster, M., Pertile, P., & Burman, C. F. (2016). Late‐stage pharmaceutical R&D and pricing policies under two‐stage regulation. Journal of Health Economics, 50, 298–311.

17. Kaltenboeck, A., & Bach, P. B. (2018). Value‐based pricing for drugs: Theme and variations. JAMA, 319(21), 2165–2166.
    Paper not yet in RePEc: Add citation now
    
18. Kleinke, J. D. (2001). The price of progress: Prescription drugs in the health care market. Health Affairs, 20(5), 43–60.
    Paper not yet in RePEc: Add citation now
    

19. Levaggi, R. (2014). Pricing schemes for new drugs: A welfare analysis. Social Science and Medicine, 102, 69–73.

20. Levaggi, R., & Pertile, P. (2020). Value‐based pricing alternatives for personalised drugs: Implications of asymmetric information and competition. Applied Health Economics and Health Policy, 18(3), 357–362. https://doi.org/10.1007/s40258-019-00541-z.

21. Levaggi, R., & Pertile, P. (2020). Which value‐based prices when patients are heterogeneous? Health Economics.

22. McGuire, A., Raikou, M., & Kanavos, P. (2008). Pricing pharmaceuticals: Value based pricing in what sense. Eurohealth, 14(2), 3–5.
    Paper not yet in RePEc: Add citation now
    
23. Mitchell, E. M. (2019). Concentration of health expenditures and selected characteristics of high spenders, U.S. Civilian Noninstitutionalized Population 2016.
    Paper not yet in RePEc: Add citation now
    
24. OECD. (2017). Health at a glance 2017: OECD indicators. Paris, France: OECD Publishing. https://doi.org/10.1787/health_glance-2017-en.
    Paper not yet in RePEc: Add citation now
    

25. Paris, V., Devaux, M., & Wei, L. (2010). Health systems institutional characteristics: A Survey of 29 OECD Countries (OECD Health Working Papers No. 50). Paris, France: OECD Publishing. https://doi.org/10.1787/5kmfxfq9qbnr-en.

26. Schork, N. (2015). Personalized medicine: Time for one‐person trials. Nature, 520, 609–611.
    Paper not yet in RePEc: Add citation now
    

27. Varol, N., Costa‐Font, J., & McGuire, A. (2012). Does adoption of pharmaceutical innovation respond to changes in the regulatory environment?. Applied Economic Perspectives and Policy, 34(3), 531–553.

28. Yu, N., Helms, Z., & Bach, P. B. (2017). R&D costs for pharmaceutical companies do not explain elevated US drug prices. Paris, France: Health Affairs Blog. Retrieved from https://www.healthaffairs.org/do/10.1377/hblog20170307.059036/full/.
    Paper not yet in RePEc: Add citation now
    

29. Zweifel, P., Steinmann, L., & Eugster, P. (2005). The Sisyphus syndrome in health revisited. International Journal of Health Care Finance and Economics, 5(2), 127–145.

1. Insurance barriers and inequalities in health care access: evidence from dual practice. (2024). Blankart, Katharina ; Goetjes, Eva.
   In: Health Economics Review.
   RePEc:spr:hecrev:v:14:y:2024:i:1:d:10.1186_s13561-024-00500-y.

   Full description at Econpapers || Download paper

2. Lifetime costs of overweight and obesity in Italy. (2024). Giaccherini, Matilde ; Belotti, Federico ; Atella, Vincenzo ; Sbraccia, Paolo ; Medea, Gerardo ; Nicolucci, Antonio ; Mortari, Andrea Piano.
   In: Economics & Human Biology.
   RePEc:eee:ehbiol:v:53:y:2024:i:c:s1570677x24000182.

   Full description at Econpapers || Download paper

3. Health status and the Great Recession. Evidence from electronic health records. (2022). Piano Mortari, Andrea ; Palma, Alessandro ; Kopinska, Joanna ; Belotti, Federico.
   In: Health Economics.
   RePEc:wly:hlthec:v:31:y:2022:i:8:p:1770-1799.

   Full description at Econpapers || Download paper

4. Aggregate Online Brand Name Pharmacy Price Dynamics for the United States and Mexico. (2022). Fullerton, Steven.
   In: Economies.
   RePEc:gam:jecomi:v:10:y:2022:i:5:p:112-:d:813776.

   Full description at Econpapers || Download paper

5. Adherence during COVID-19: The role of aging and socio-economics status in shaping drug utilization. (2022). LEVAGGI, ROSELLA ; Leporatti, Lucia ; Montefiori, Marcello ; di Novi, Cinzia.
   In: Journal of Economic Behavior & Organization.
   RePEc:eee:jeborg:v:204:y:2022:i:c:p:1-14.

   Full description at Econpapers || Download paper

6. Beyond price: the effects of non-financial barriers on access to drugs and health outcomes. (2021). LEVAGGI, ROSELLA ; Leporatti, Lucia ; Montefiori, Marcello.
   In: The European Journal of Health Economics.
   RePEc:spr:eujhec:v:22:y:2021:i:4:d:10.1007_s10198-021-01270-8.

   Full description at Econpapers || Download paper

7. Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?. (2021). Versaevel, Bruno ; Billette de Villemeur, Etienne ; Scannell, Jack.
   In: MPRA Paper.
   RePEc:pra:mprapa:108233.

   Full description at Econpapers || Download paper

8. Opening up Military Innovation: Causal Effects of Bottom-up Reforms to U.S. Defense Research. (2021). van Reenen, John ; Howell, Sabrina T ; Wong, Jun ; Rathje, Jason.
   In: IZA Discussion Papers.
   RePEc:iza:izadps:dp14297.

   Full description at Econpapers || Download paper

9. Opening up military innovation: causal effects of reforms to US defense research. (2021). van Reenen, John ; Howell, Sabrina T ; Wong, Jun ; Rathje, Jason.
   In: LSE Research Online Documents on Economics.
   RePEc:ehl:lserod:114430.

   Full description at Econpapers || Download paper

10. Opening up military innovation: causal effects of bottom-up reforms to U.S. defense research. (2021). van Reenen, John ; Howell, Sabrina T ; Wong, Jun ; Rathje, Jason.
    In: CEP Discussion Papers.
    RePEc:cep:cepdps:dp1760.

    Full description at Econpapers || Download paper

11. Older patients and geographic barriers to pharmacy access: When nonadherence translates to an increased use of other components of health care. (2020). Leporatti, Lucia ; Di Novi, Cinzia ; Montefiori, Marcello.
    In: Health Economics.
    RePEc:wly:hlthec:v:29:y:2020:i:s1:p:97-109.

    Full description at Econpapers || Download paper

12. Research funding and price negotiation for new drugs. (2020). Jelovac, Izabela ; Barigozzi, Francesca.
    In: Health Economics.
    RePEc:wly:hlthec:v:29:y:2020:i:s1:p:83-96.

    Full description at Econpapers || Download paper

13. Innovation, aging, and health care: Unraveling “silver” from “red” herrings?. (2020). LEVAGGI, ROSELLA ; Costa-Font, Joan ; Costafont, Joan.
    In: Health Economics.
    RePEc:wly:hlthec:v:29:y:2020:i:s1:p:3-7.

    Full description at Econpapers || Download paper

14. Explaining the causal effect of adherence to medication on cholesterol through the marginal patient. (2020). Depalo, Domenico.
    In: Health Economics.
    RePEc:wly:hlthec:v:29:y:2020:i:s1:p:110-126.

    Full description at Econpapers || Download paper

15. Are patients more adherent to newer drugs?. (2020). Lichtenberg, Frank ; Blankart, Katharina.
    In: Health Care Management Science.
    RePEc:kap:hcarem:v:23:y:2020:i:4:d:10.1007_s10729-020-09513-5.

    Full description at Econpapers || Download paper

16. Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany. (2020). Blankart, Katharina ; Arndt, Friederike.
    In: IJERPH.
    RePEc:gam:jijerp:v:17:y:2020:i:11:p:4113-:d:369171.

    Full description at Econpapers || Download paper

17. The development of complex and controversial innovations. Genetically modified mosquitoes for malaria eradication. (2020). Cisnetto, Valentina ; Barlow, James.
    In: Research Policy.
    RePEc:eee:respol:v:49:y:2020:i:3:s0048733319302355.

    Full description at Econpapers || Download paper

18. Explaining the causal effect of adherence to medication on cholesterol through the marginal patient. (2019). Depalo, Domenico.
    In: Health, Econometrics and Data Group (HEDG) Working Papers.
    RePEc:yor:hectdg:19/13.

    Full description at Econpapers || Download paper

19. When Technological Advance Meets Physician Learning in Drug Prescribing. (2019). Depalo, Domenico ; Belotti, Federico ; Atella, Vincenzo ; Bhattacharya, Jay.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:26202.

    Full description at Econpapers || Download paper

Report date: 2025-10-04 17:55:41 || Missing content? Let us know